I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASN 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Oct 24 / Roche and Genentech
Comparability of Two Anti-PLA2R ELISAs in Patients With Primary Membranous Nephropathy
This study compared the concordance between two anti-PLA2R assays used to measure anti-PLA2R antibody levels: the historical Brenchley ELISA and the new, widely available EuroImmun-ELISA, which is being used in the ongoing Phase III MAJESTY clinical trial (NCT04629248). The study also sought to determine the distribution of baseline serum anti-PLA2R levels to inform stratification thresholds for the MAJESTY trial.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 24 / Roche and Genentech
MAJESTY: A Phase III, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
This presentation outlines the study design of the Phase III MAJESTY clinical trial (NCT04629248), which is assessing the efficacy and safety of obinutuzumab versus tacrolimus in patients with primary membraneous nephropathy. Study recruitment and baseline characteristics are also presented.
05:00 PM
Duration 2hrs San Diego, CA
Comparability of Two Anti-PLA2R ELISAs in Patients With Primary Membranous Nephropathy
Barbour SJ, Clarke H, Berisha E, Arjomandi A, Chen D, Riboulet W, Boston H, Prot S, Cattran DC, Place DE

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 PM
Duration 10mins Room 1 (Convention Center)
MAJESTY: A Phase III, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
Fervenza F, Gesualdo L, Kirsztajn GM, Hou FF, Appel G, Prot S, Berisha E, Khatri L, Parsons T, Spinks E, Boston H, Riboulet W, Han X, Chen DC, Bomback A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar